Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INSM – Insmed Incorporated

Float Short %

4.24

Margin Of Safety %

Put/Call OI Ratio

1.05

EPS Next Q Diff

0.43

EPS Last/This Y

-0.64

EPS This/Next Y

2.56

Price

204

Target Price

222.78

Analyst Recom

1.15

Performance Q

39.08

Relative Volume

0.94

Beta

1.07

Ticker: INSM




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10INSM191.440.940.09112976
2025-11-11INSM193.820.921.74114154
2025-11-12INSM194.40.930.76114538
2025-11-13INSM190.960.920.30115072
2025-11-14INSM193.180.923.87115678
2025-11-17INSM197.460.951.16117774
2025-11-18INSM201.640.960.19118223
2025-11-19INSM203.470.930.58120895
2025-11-20INSM199.660.930.26120983
2025-11-21INSM198.710.950.79120855
2025-11-24INSM207.570.900.6172321
2025-11-25INSM209.020.900.3873105
2025-11-26INSM204.420.922.4973463
2025-12-01INSM211.620.930.6975159
2025-12-02INSM206.620.941.1876176
2025-12-03INSM206.720.975.6179857
2025-12-04INSM204.991.020.6281715
2025-12-05INSM203.941.051.7982939
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10INSM191.92-3.4497.9-6.11
2025-11-11INSM193.69-3.4499.6-6.11
2025-11-12INSM194.44-3.4502.8-6.11
2025-11-13INSM191.00-3.4515.8-6.11
2025-11-14INSM193.23-3.4497.8-6.11
2025-11-17INSM197.45-3.4491.7-6.11
2025-11-18INSM201.59-3.4505.3-6.11
2025-11-19INSM203.56-3.4512.3-6.11
2025-11-20INSM199.74-3.4516.5-6.11
2025-11-21INSM198.73-3.6508.0-6.13
2025-11-24INSM206.94-3.6479.5-6.13
2025-11-25INSM209.02-3.6498.5-6.13
2025-11-26INSM204.54-3.6518.2-6.13
2025-12-01INSM211.66-3.6493.7-6.13
2025-12-02INSM206.60-3.6519.1-6.13
2025-12-03INSM206.78-3.6504.6-6.13
2025-12-04INSM205.04-7.4510.2-6.21
2025-12-05INSM204.00-7.4508.2-6.21
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10INSM-21.473.154.53
2025-11-11INSM-21.473.154.53
2025-11-12INSM-21.473.153.84
2025-11-13INSM-21.933.153.84
2025-11-14INSM-22.373.153.84
2025-11-17INSM-21.4510.723.84
2025-11-18INSM-23.0710.723.84
2025-11-19INSM-23.0710.723.84
2025-11-20INSM-22.9010.723.84
2025-11-21INSM-22.9010.723.84
2025-11-24INSM-22.530.593.82
2025-11-25INSM-28.300.593.82
2025-11-26INSM-28.390.594.25
2025-12-01INSM-28.390.554.25
2025-12-02INSM-28.390.554.25
2025-12-03INSM-28.540.554.25
2025-12-04INSM-28.090.554.25
2025-12-05INSM-27.810.554.24
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-1.75

Avg. EPS Est. Current Quarter

-1.42

Avg. EPS Est. Next Quarter

-1.32

Insider Transactions

-27.81

Institutional Transactions

0.55

Beta

1.07

Average Sales Estimate Current Quarter

170

Average Sales Estimate Next Quarter

194

Fair Value

Quality Score

34

Growth Score

53

Sentiment Score

85

Actual DrawDown %

4.1

Max Drawdown 5-Year %

-63.3

Target Price

222.78

P/E

Forward P/E

PEG

P/S

97.33

P/B

45.86

P/Free Cash Flow

EPS

-6.18

Average EPS Est. Cur. Y​

-6.21

EPS Next Y. (Est.)

-3.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-264.83

Relative Volume

0.94

Return on Equity vs Sector %

-152.1

Return on Equity vs Industry %

-137.2

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.1

EBIT Estimation

508.2
Insmed Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 1271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading